CIRM Funded Clinical Trials

A Phase 3, Randomized, Placebo-controlled Multicenter Study to Evaluate Efficacy & Safety of Repeated Administrations of NurOwn® in Patients with ALS


Ralph Kern
Investigator:
CIRM Grant:
Award Value:
$15,912,390
Trial Stage: 
Phase 3
Trial Status: 
Recruiting
Targeted Enrollment:
200
ClinicalTrials.gov ID:
Details: 

ALS is a fatal neurodegenerative disease for which there is currently no adequate treatment. Autologous MSCs are propagated ex vivo and induced to secrete neurotrophic factors. NurOwn cells are returned to the patients in the target area of damage. Previous trials showed safety and encouraging signs of efficacy. 

Design: 

Randomized, double blind, placebo-controlled multi-site study.

Goal: 

Safety and efficacy of three repeated doses.

Status: 

Actively recruiting.